Skip to content
AnalystLens

BrynMDTK

Legal name
Bryn Inc.
Sector
Other
Industry
Services-Management Services

Stock Price $MDTK

Latest filings

You are here#1 of 87 in Industrials by market cap

Filing record · 2020–202610-K910-Q108-K6

MDTK filed 9 annual reports (10-K), 10 quarterly reports (10-Q) and 6 current reports (8-K) between 2020 and 2026.

  1. Change in control8-K · Feb ’21Feb ’21
  2. FY2024 annual report10-K · Apr ’25Apr ’25

01—Key figures

Share Class

Last reported FY2012

Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  3. $21,000
YoY changeLatest −48.7%

Latest bar from 10-KFY2012Click a bar to open its SEC filing

View full history →
All MDTK Financial Metrics41 metrics

Income Statement14

Balance Sheet17

Cash Flow7

Per Share3

02—Overview

Bryn Financial Overview 2021–2025

Updated Oct 10, 2026

Despite racking up a staggering accumulated deficit of over $117.5 milliona by Q3 2025, MEDO Technologies, Inc. (formerly Byrn, Inc.) has generated exactly $0 in revenue over the last half-decade. This total lack of commercial traction underscores a highly speculative investment thesis: the firm functions purely as a dormant shell attempting a high-wire pivot into an AI-driven pharmaceutical distributor. Surviving solely on interest-free related-party loans, MEDO remains entirely dependent on dilutive financing to fund its newly proposed acquisition strategy.

The operational timeline highlights persistent financial distress. The company's trajectory derailed after a voided share exchange triggered an $87.6 millionb goodwill impairment in FY2021, effectively halting operations. By the close of FY2025, the balance sheet had flatlined, reporting exactly $0 in total assets alongside a stockholders' deficit of $96,612. Recent quarters show widening cash burn under new management, with net losses accelerating to $178,646 in Q2 2026, a massive jump from just $8,472 in the same period a year earlier.

To pave the way for its strategic rebrand, ownership implemented a severe 1-for-100,000 reverse stock split in September 2026, following MEDO Healthcare LLC's purchase of voting control for a mere $175,000c in May 2026. Despite lacking tangible operations, speculative market activity valued the pre-revenue shell at $24 million at the close of FY2025, with shares trading at $0.06. With zero operating cash flow, future viability hinges entirely on unproven structural pivots.

Recent Developments (Q1 and Q2 2026)

Following a sweeping executive overhaul in May 2026, John Leo and Arthur Magee replaced David Lazar as CEO and CFO to spearhead the company's new strategic direction. Before his exit, Lazar settled $93,285d of related-party debt by receiving 30,015,577 newly issued shares, pushing the outstanding count to 450,000,000 in Q1 2026. During this period, the net loss widened to $30,937, up from $16,410 a year earlier. By Q2 2026, total liabilities swelled to $206,170 against a mere $1,909 in assets, prompting management to highlight severe material weaknesses in internal controls.

Bulls can argue that the injection of experienced corporate finance leadership provides a theoretical foundation for executing future acquisitions. Conversely, the stock appears vastly overvalued relative to recent performance, commanding a $56 millione market capitalization alongside $0.00 in annual EPS, resulting in an N/A P/E ratio as of August 14, 2026.

What to watch: progress on securing acquisition capital; remediation of internal control weaknesses under the new executive team

03—Filings

Recent SEC Filings

  1. 8-KBryn 8-K Report, Bylaw Amendment (Sep 16, 2026)Byrn, Inc. (BRRN) has filed an 8-K announcing significant corporate changes set to take effect on September 23, 2026. Most notably, the company will undergo a substantial one-for-one-hundred-thousand (1-for-100,000) reverse stock split. This action is designed to dramatically reduce the number of outstanding shares. Additionally, the company will officially change its name to MEDO Technologies, Inc., and has applied to trade under the ticker symbol "MEDO". This reverse stock split is an aggressive move that will impact all shareholders. Those holding fewer than 100,000 shares prior to the split will receive a nominal cash payment of $0.00007 per share, effectively cashing them out. Holders of 100,000 or more shares will have fractional shares rounded up to the nearest whole share. The adjusted trading is expected to commence on the OTCID Market on September 24, 2026, with a new CUSIP number. Investors should carefully consider the implications of this significant share consolidation.
  2. 8-KBryn 8-K Report, Change in Control (May 11, 2026)Byrn, Inc. (BRRN) has undergone a significant change in control and leadership. MEDO Healthcare LLC has acquired a controlling stake of approximately 84.7% of the company's voting power through the purchase of 10 million shares of Series A-1 Preferred Stock for $175,000. This transaction, which occurred on April 24, 2026, has resulted in a substantial shift in beneficial ownership, with Jean Christophe Chopin now holding 63.1% of the common stock, but MEDO Healthcare LLC wielding dominant voting power due to the preferred stock. Concurrently, David Lazar has resigned as the sole director and officer. John Leo has been appointed as the new Chief Executive Officer and sole director, and Arthur Magee has been appointed as CFO and Secretary. Both Leo and Magee bring extensive experience in investment banking and corporate finance from Primary Capital LLC, suggesting a strategic focus on financial operations and potential growth initiatives.
  3. 8-KBryn 8-K Report, Material Agreement (Feb 16, 2021)This 8-K filing from Born, Inc. (BRRN) details a significant corporate transformation, primarily through a share exchange agreement with Alkeon Creators, Inc. effective February 16, 2021. This transaction has been accounted for as a recapitalization, with Alkeon being the accounting acquirer. This strategic move has effectively resulted in a reverse merger, with the former stockholders of Alkeon now holding a majority of the outstanding common stock and Born, Inc. ceasing to be a shell company. The company has also undergone a name change from Quture International, Inc. to Born Inc. and a 1-for-1,000 reverse stock split. The company is repositioning itself as a holding company specializing in digital, data-led solutions for retail supply chains, operating through its subsidiary Alkeon. Alkeon provides B2B solutions for digitizing tradeshows and showrooms, alongside the Born.com platform that connects luxury design brands with retailers. The business model is primarily subscription-based. The filing also highlights a change in leadership with Mr. Jean Christophe Chopin appointed as the sole officer and director, replacing Mr. Wieland Kreuder.
  4. 8-KBryn 8-K Report, Bylaw Amendment (Feb 10, 2021)This Form 8-K, filed February 10, 2021 by Born, Inc. (a Nevada corporation; the request refers to it as Byrn, Inc. (BRRN), but the filing itself names Born, Inc.), reports a single corporate action under Item 5.03: the Board changed the company's fiscal year end to December 31. The sole director, Wieland Kreuder, approved the change by written consent on February 4, 2021. The stated reason is to align the company's fiscal year with that of its intended subsidiary, Alkeaon Creators Inc. The filing does not disclose the prior fiscal year end, any transition period, or the financial impact of the change. The cover page lists no securities registered under Section 12(b), and the trading symbol and exchange fields are all marked N/A. The company therefore appears to have no exchange-listed securities, which makes this filing an administrative disclosure rather than an operating update. Exhibit 99.1 contains the sole director's resolutions, which also ratify prior company actions and authorize officers to make the necessary filings. For investors, the filing signals an early-stage or restructuring-phase company preparing to acquire or form a subsidiary, and it provides no revenue, earnings, balance sheet, or deal terms. Any investment thesis would depend on later filings that describe the Alkeaon Creators relationship and the company's financial condition.
  5. 8-KBryn 8-K Report, Bylaw Amendment (Dec 1, 2020)Byrn, Inc. (BRRN), formerly Quture International, Inc., has filed an 8-K report detailing significant corporate actions taken on November 24, 2020, and effective December 1, 2020. The company has officially changed its name to Byrn, Inc. and executed a 1-for-1,000 reverse stock split. These changes are strategically positioned in anticipation of the company entering a new line of business operations. Investors should note that FINRA has declared these changes effective as of December 1, 2020. Furthermore, the company was informed that its ticker symbol will be updated to BRRN within twenty business days. This rebranding and restructuring signals a potential shift in the company's strategic direction, and investors should monitor future filings for details regarding the new business ventures.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.